Why Did Guardant Health Stock Jump?

For questions about this article or underlying research, email help@trefis.com.

Guardant Health (GH) stock gained 143.8% in the year to October 23, 2026, against 14.5% for the S&P 500. During that period, the FDA approved the company’s Guardant360 Liquid CDx blood test on May 20, and the American Cancer Society added the Shield colon cancer screening test to its guidelines a week later. So how much of that rise came from higher sales, and how much from investors paying more for each dollar of them?

Investors Now Pay Twice As Much For Guardant’s Sales

Sales explain only part of the rise. Guardant generated $1,183 million in revenue over the four quarters to June 30, 2026, up 42.7% from a year earlier. Over the same stretch, investors more than doubled what they pay for that revenue, valuing the stock at 20.0 times sales at the end of September 2026, against 9.4 times a year before. Both multiples are measured at the end of September, not October 23, so they cover a different year than the 143.8% gain and do not add up to it. The company’s peers saw mixed returns over the same year: Natera gained 107%, while Tempus AI fell 22%. Ultimately, the price on each dollar of Guardant’s sales climbed much faster than the sales themselves.

What Changed In Guardant Health’s Business In 2026?

Developments around two tests shifted Guardant’s business: a new blood test secured FDA approval, and the previously available Shield test gained a guideline listing alongside insurance coverage. Guardant stock rose 17.1% on the day of the FDA approval, an advance that news reports that day tied to the regulatory decision. Following the guideline listing, UnitedHealth Group, the largest commercial insurer in the United States, began covering Shield on August 1. Management said on the July 30, 2026 call that the UnitedHealth decision arrived much sooner than it had expected.

Shield is expanding rapidly from a small base. Shield tests increased to about 66,000 in the second quarter of 2026, up from 16,000 a year earlier. Screening revenue reached $53 million in that quarter, compared with $15 million a year before. Screening still accounted for only about 16% of the quarter’s $335 million in revenue, and most of Guardant’s sales still come from its Oncology business. Management also raised its full-year 2026 revenue forecast to a range of $1.34 billion to $1.36 billion, representing growth of 36% to 38%.

Guardant Health Still Loses As Much As Before

Guardant’s losses have not narrowed in dollar terms. The company recorded an operating loss of $470 million over the four quarters to June 30, 2026, compared with a $461 million shortfall a year earlier. Sales grew faster than costs, making the loss smaller against revenue and improving the operating margin to -39.7% from -55.6%. Even with that improvement, the company spent $241 million more cash than it brought in over those twelve months.

Investors now pay far more for Guardant’s sales than they did a year ago, but the company’s losses remain where they were. Free cash flow, which management aims to bring to breakeven across the company by the end of 2027, is the number to watch when Guardant reports in November 2026.

Is Too Much Of Your Wealth Riding On One Stock?

Guardant Health holders just watched the stock move sharply higher. When one position grows into a large part of your wealth, a sharp fall can hurt your whole plan, and selling to spread the money out can bring a large tax bill. Our partner advisory firm offers a free strategy review of ways to protect a concentrated position and unwind it with less tax.

Request A Free Strategy Review

Spot an error or want more like this? Tell us in 10 seconds.